Related Experiment Video

Updated: Feb 5, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.7K

Complement Complex C5b-9 Levels Are Associated with the Clinical Outcomes of Acute Ischemic Stroke and Carotid Plaque

Weixin Si1, Pingping He1, Yi Wang1

  • 1Department of Neurology, The Affiliated Shengjing Hospital of China Medical University, No. 36 Sanhao Street, Heping District, Shenyang, 110004, China.

Translational Stroke Research
|September 3, 2018
PubMed

Insights

Elevated levels of the terminal complement complex C5b-9 in acute ischemic stroke (AIS) patients correlate with stroke severity, poor outcomes, and unstable carotid plaques, suggesting it as a potential biomarker.

Area of Science:

  • Immunology
  • Neurology
  • Cardiovascular Science

Background:

  • The terminal complement complex C5b-9 is implicated in acute ischemic stroke (AIS) and carotid atherosclerosis.
  • The relationship between serum C5b-9 levels, AIS severity, patient outcomes, and carotid plaque stability requires further investigation.

Purpose of the Study:

  • To investigate the association between serum C5b-9 levels and the severity, outcome, and carotid plaque stability in patients with AIS.

Main Methods:

  • Enzyme-linked immunosorbent assay (ELISA) was used to measure serum C5b-9 levels in 70 AIS patients and 70 healthy controls at 72 hours post-stroke.
  • Evaluations included infarct size, National Institutes of Health Stroke Scale (NIHSS), 90-day modified Rankin Scale (mRS), and carotid plaque characteristics.

Main Results:

  • Serum C5b-9 levels were significantly higher in AIS patients compared to controls (p < 0.001).
  • C5b-9 levels correlated with infarct size (p = 0.045) and NIHSS scores (p = 0.035).
  • Higher C5b-9 levels were observed in patients with poor 90-day outcomes (p < 0.001) and unstable carotid plaques (p = 0.009).
  • Multivariate analysis identified C5b-9 as an independent risk factor for AIS (p < 0.001) and unstable carotid plaques (p = 0.015).

Conclusions:

  • Serum C5b-9 may serve as a valuable biomarker for predicting AIS severity and patient outcomes.
  • C5b-9 levels are associated with carotid plaque instability in AIS patients.
  • These findings highlight the potential of C5b-9 as a therapeutic target in managing AIS and associated carotid atherosclerosis.

Keywords:
Acute ischemic strokeCarotid atherosclerosisTerminal complement complex C5b-9mRS

More Related Videos

Primary Outcome Assessment in a Pig Model of Acute Myocardial Infarction14:19

Primary Outcome Assessment in a Pig Model of Acute Myocardial Infarction

Published on: October 14, 2016

12.1K
Author Spotlight: Establishing a Reliable Distal MCA Occlusion Model in Mice for Stroke Research07:34

Author Spotlight: Establishing a Reliable Distal MCA Occlusion Model in Mice for Stroke Research

Published on: December 15, 2023

3.4K

Related Concept Videos

Complexation Equilibria: Factors Influencing Stability of Complexes01:09

Complexation Equilibria: Factors Influencing Stability of Complexes

In complexation reactions, metal cations are the electron pair acceptors, and the ligands are the electron pair donors. The stability of the metal complexes depends primarily on the complexing ability of the central metal ion and the nature of the ligands. Generally, the complexing ability of the metal ion depends on the size and charge of the ion. As the metal ion size increases, the stability of the metal complexes decreases, provided that the valency of the metal ion and the ligands remain...
855
Acute Pancreatitis II: Clinical Manifestations and Management01:30

Acute Pancreatitis II: Clinical Manifestations and Management

Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
877
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
436
Acute Kidney Injury III: Clinical Manifestations01:29

Acute Kidney Injury III: Clinical Manifestations

Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
950
Complement System01:27

Complement System

The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a...
10.8K
Complementation Tests00:49

Complementation Tests

A complementation test is a simple cross to identify whether the two mutations are located on the same gene or different genes. It was first performed by Edward Lewis in the 1940s while working on fruit flies. He developed the test to identify the location and arrangement of different mutations on chromosomes.
Organisms heterozygous for different mutations are crossed pairwise in all combinations. If present on different genes, the mutations can complement each other by providing the missing...
6.3K